Motapizone

Overview

Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Phosphodiesterase (PDE)

Product Information

• Catalog No.: HY-106739
• CAS No.: 90697-57-7
• Molecular Formula: C12H12N4OS
• Molecular Weight: 260.31
• Purity: 95.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source